secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950170-24-027958
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta reports Q4 2023 net loss of $13.8M; cash $53.7M; NAVAL-1 enrollment complete; runway extended to mid-Q1 2025
--------------------------------------------------------------------------------

- Net loss Q4 2023 $13.8M ($0.35/sh) vs $10.3M ($0.27) Q4 2022; full year $51.1M ($1.32) vs $49.2M ($1.30).
- Cash and short-term investments $53.7M at Dec 31, 2023; pro forma cash runway extended into mid-Q1 2025 via $5M prepayment and loan amendments.
- Received $5M non-dilutive from Day One biopharma for milestone monetization; amended SVB-Oxford loan with $5M prepayment, interest-only through June 2024.
- Completed Stage 2 enrollment in NAVAL-1 trial for R/R EBV+ PTCL; Stage 1 topline data expected Q2 2024; FDA engagement mid-2024 for accelerated approval.
- Phase 1b/2 solid tumor study completed sixth dose cohort; RP2D expected H2 2024; ODD granted for nasopharyngeal carcinoma in December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/virx-20240301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer